IH02 - Accelerate Authoring Across R&D Documents: AI Tool Demos for CSR, CTD, Non-Clinical & CMC

IH02 - Accelerate Authoring Across R&D Documents: AI Tool Demos for CSR, CTD, Non-Clinical & CMC

Tuesday, March 24, 2026 12:05 PM to 12:30 PM · 25 min. (Europe/Amsterdam)
Exhibition Hall/Innovation Hub (3rd floor)
Sponsored Session
Track 1 - Artificial Intelligence & RWE

Information

This session presents practical approaches to AI-orchestrated authoring and quality control for regulatory and medical writing across the R&D document lifecycle, spanning clinical, non-clinical, quality, safety, labeling, and regulatory submission–related documents. 
We demonstrate how teams can work in familiar environments—such as a Microsoft Word add-in and a web portal—while automating up to 90% of first-draft content in alignment with regulatory guidance. The approach streamlines review comment incorporation, document finalization, quality control, and subsequent updates to accelerate submission timelines. 
The workflow integrates with enterprise systems, including Veeva RIM, supporting the end-to-end lifecycle of regulatory submissions alongside existing document management and review processes. 
Finally, we introduce an R&D document-network model for change intelligence, enabling automated change detection, dependency mapping for impact assessment, visible change lineage, and downstream propagation—supporting cross-document consistency and scalable QC. 

AlphaLife SciencesD10About Company The AlphaLife Sciences team is uniquely positioned to lead this category, combining world-class engineering talent—over 80% from Google, Verily, Microsoft, and Veeva—with deep domain expertise in pharma, regulatory writing, and clinical development. Our technical leadership is validated by formal selection into the technology programs of Microsoft, Google, NVIDIA, Veeva, and JLABS, as well as our role as Microsoft’s strategic AI content authoring partner for life sciences. This foundation enables the rapid, production-grade deployment of advanced AI—including RAG, agentic AI, and multi-agent systems—within a rigorously engineered, compliant platform already adopted by more than half of the global top-20 pharmaceutical companies. Backed by an advisory network that includes the former head of new drug review at the FDA, along with senior leaders from major pharma companies, CROs, and specialized life-sciences consultancies, the team consistently delivers enterprise-scale, regulatory-grade impact. Vision, Mission, and Key Pillar Products Our Vision is to accelerate global drug development—making it faster and more affordable through AI. Our Mission is to automate life-science content authoring and insight generation with AI, enabling biopharma teams to achieve greater efficiency, quality, and compliance. Our four pillar product lines, in both production and roadmap, are delivered through the AuroraPrime suite—a scalable, hyperscaler-powered GenAI platform built on Content Authoring, Content Insights, an AI Platform for Developers, and 360° Clinical Efficiency—together enabling true end-to-end drug lifecycle transformation.